NASDAQ:MYLMylan Stock Price, Forecast & News

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MYL stock has increased by 18.6% and is now trading at $17.16. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

Mylan is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mylan.

Mylan NV (NASDAQ:MYL) announced its quarterly earnings data on Monday, May, 11th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. The business had revenue of $2.62 billion for the quarter, compared to analysts' expectations of $2.65 billion. Mylan had a return on equity of 20.00% and a net margin of 0.54%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.82 earnings per share. View Mylan's earnings history.

Mylan issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.

14 Wall Street analysts have issued twelve-month price objectives for Mylan's stock. Their forecasts range from $17.00 to $34.50. On average, they anticipate Mylan's stock price to reach $23.46 in the next year. This suggests a possible upside of 36.7% from the stock's current price. View analysts' price targets for Mylan.

Headlines about MYL stock have been trending negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutMylan.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (11.00%), State Street Corp (4.48%), Pzena Investment Management LLC (3.79%), AQR Capital Management LLC (2.20%), Geode Capital Management LLC (1.93%) and Invesco Ltd. (1.72%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View institutional ownership trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Camber Capital Management LP, Nuveen Asset Management LLC, Pzena Investment Management LLC, Morgan Stanley, Morgan Stanley, Magnetar Financial LLC, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Iridian Asset Management LLC CT, Wellington Management Group LLP, AQR Capital Management LLC, First Manhattan Co., Retirement Systems of Alabama, AXA, and Acadian Asset Management LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. View insider buying and selling activity for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $17.16.

Mylan has a market capitalization of $8.87 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

The official website for Mylan is www.mylan.com.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]